Intervention
Dabrafenib
ClinicalTrials.gov intervention label
Clinical trials
12 shownDETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.NCT07440290 · 2026-04-01
RECRUITINGERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung CancerNCT06532149 · 2024-08-05
UNKNOWNA Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLCNCT04452877 · 2020-08-19
COMPLETEDJSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway MutationsNCT04418167 · 2020-06-18
SUSPENDEDSerial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialNCT03878524 · 2020-04-01
TERMINATEDStudy of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLCNCT02672358 · 2018-09-03
WITHDRAWNTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)NCT02465060 · 2015-08-17
ACTIVE_NOT_RECRUITINGStudy to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 MutationsNCT02124772 · 2015-01-15
COMPLETEDA Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)NCT02130466 · 2014-05-29
COMPLETEDPhase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib AloneNCT02027961 · 2013-12-20
COMPLETEDStudy of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.NCT01336634 · 2011-08-05
COMPLETEDManaged Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung CancerNCT04507919
NO_LONGER_AVAILABLECommon conditions
Cancer3Melanoma3Glioma2Multiple Myeloma2Refractory Malignant Solid Neoplasm2Solid Tumors2Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive1Advanced Lymphoma1Advanced Malignant Solid Neoplasm1Anatomic Stage IV Breast Cancer AJCC v81Anemia1Ann Arbor Stage III Hodgkin Lymphoma1Ann Arbor Stage III Non-Hodgkin Lymphoma1Ann Arbor Stage IV Hodgkin Lymphoma1Ann Arbor Stage IV Non-Hodgkin Lymphoma1Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative1Bladder Carcinoma1Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive1Breast Carcinoma1Carcinoma, Non-Small Cell-Lung1Carcinoma, Non-Small-Cell Lung1Castration-Resistant Prostate Carcinoma1Cervical Carcinoma1Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive1Colon Carcinoma1
Leading sponsors
Trial status mix
COMPLETED5
ACTIVE_NOT_RECRUITING1
NO_LONGER_AVAILABLE1
RECRUITING1
SUSPENDED1
TERMINATED1
UNKNOWN1
WITHDRAWN1
Phase mix
PHASE27
PHASE15
PHASE31
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.